Literature DB >> 10617705

Clinical and histologic features of chronic hepatitis C virus infection after blood transfusion in Japanese children.

A Hoshiyama1, A Kimura, T Fujisawa, M Kage, H Kato.   

Abstract

OBJECTIVE: To characterize the clinical and histologic features of chronic hepatitis C virus (HCV) infection after blood transfusion in Japanese children. STUDY
DESIGN: We studied 231 children with a history of blood product transfusion. Patients were divided into two groups: 116 patients with a history of malignant disease (group 1), 115 patients who had undergone open heart surgery (group 2). We examined changes in serum alanine aminotransferase (ALT) activity and HCV markers, and patients' clinical course. Moreover, in 38 patients in whom the time of HCV infection could be defined, we examined liver histology.
RESULTS: The proportions of patients in each group who were anti-HCV-positive were 35 out of 116 (30%) and 20 out of 115 (17%), respectively. Of the anti-HCV-positive patients, the proportions of HCV RNA-positive patients in each group were 30 out of 35 (86%) and 12 out of 20 (60%), respectively. Levels of ALT activity in patients with HCV infection varied widely for several years after blood transfusion; thereafter ALT activity fell to <100 IU/L in 2 groups. Serum ALT activity in patients who were HCV RNA-negative became normal. With regard to liver histology, there were no differences in the grade of necroinflammation or stage of fibrosis in patients with different durations of infection or when patients were analyzed according to the presence or absence of malignant disease. Patients mostly had grade 2-4 inflammation and stage 1-2 fibrosis. Thus, chronic hepatitis C was a morphologically mild disease in most children in this study.
CONCLUSIONS: Sixty percent to 80% of children with HCV infection in this study developed chronic hepatitis C. However, examination of liver histology findings in children with chronic hepatitis C showed only mild changes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10617705     DOI: 10.1542/peds.105.1.62

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

1.  Clinical spectrum and histopathologic features of chronic hepatitis C infection in children.

Authors:  Parvathi Mohan; Camilla Colvin; Chevelle Glymph; Roma R Chandra; David E Kleiner; Kantilal M Patel; Naomi L C Luban; Harvey J Alter
Journal:  J Pediatr       Date:  2007-02       Impact factor: 4.406

2.  Symptomatic and pathophysiologic predictors of hepatitis C virus progression in pediatric patients.

Authors:  Wendy A Henderson; Ravi Shankar; Jordan J Feld; Colleen M Hadigan
Journal:  Pediatr Infect Dis J       Date:  2009-08       Impact factor: 2.129

3.  Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study.

Authors:  Parvathi Mohan; Bruce A Barton; Michael R Narkewicz; Jean P Molleston; Regino P Gonzalez-Peralta; Philip Rosenthal; Karen F Murray; Barbara Haber; Kathleen B Schwarz; Zachary D Goodman
Journal:  Hepatology       Date:  2013-09-30       Impact factor: 17.425

4.  Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children.

Authors:  M S El-Raziky; M El-Hawary; G Esmat; A M Abouzied; N El-Koofy; N Mohsen; S Mansour; A Shaheen; M Abdel Hamid; H El-Karaksy
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

5.  Natural course of HCV infection in childhood cancer survivors.

Authors:  Francesca Fioredda; Andrea Moser; Luisella Bertoluzzo; Herwig Lackner; Raffaella Giacchino; Milena La Spina; Luisella Lazier; Caterina Riva; Mareva Giacchino; Donatella Fraschini; Eva Frey; Angela Sementa; Angela Pistorio; Riccardo Haupt
Journal:  Support Care Cancer       Date:  2009-10-27       Impact factor: 3.603

6.  Hepatitis C virus infection acquired in childhood.

Authors:  Cristina Camarero; Natalia Ramos; Alberto Moreno; Angel Asensio; Maria Luisa Mateos; Belen Roldan
Journal:  Eur J Pediatr       Date:  2007-04-12       Impact factor: 3.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.